LENZ Therapeutics, Inc. Investigated by the Portnoy Law Firm
LENZ Therapeutics, Inc. (LENZ)
Company Research
Source: GlobeNewswire
LOS ANGELES, April 23, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises LENZ Therapeutics, Inc., (“LENZ" or the "Company") (NASDAQ: LENZ) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via https://portnoylaw.com/lenz-therapeutics-inc. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses. LENZ’s stock price plummeted $6.36 per share, or 25.96%, to close at $18.14 per share on December 12, 2025, thereby injuring investors. This sharp market contraction was triggered by a December 12, 2025, emergence of safety data regarding the Company’s primary ophthalmic product. The primary driver of the valuation collapse was the public disclosure of
Show less
Read more
Impact Snapshot
Event Time:
LENZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LENZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LENZ alerts
High impacting LENZ Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LENZ
News
- LENZ Therapeutics (LENZ) had its price target lowered by HC Wainwright from $56.00 to $48.00. They now have a "buy" rating on the stock.MarketBeat
- LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United KingdomGlobeNewswire
- LENZ Therapeutics: Speculative But Strong Buy [Seeking Alpha]Seeking Alpha
- The Consensus EPS Estimates For LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Fell Dramatically [Yahoo! Finance]Yahoo! Finance
- Why Lenz Therapeutics Stock Plummeted by Almost 20% This Week [Yahoo! Finance]Yahoo! Finance
LENZ
Earnings
- 3/24/26 - Miss
LENZ
Sec Filings
- 4/28/26 - Form ARS
- 4/28/26 - Form DEFA14A
- 4/28/26 - Form DEF
- LENZ's page on the SEC website